EQS-Adhoc: Evonik Industries AG: Evonik publishes preliminary figures for the first quarter of 2024
|
EQS-Ad-hoc: Evonik Industries AG / Key word(s): Preliminary Results/Quarter Results Evonik publishes preliminary figures for the first quarter of 2024 Essen, April 16, 2024. Evonik Industries AG publishes the following preliminary key financial figures for the first quarter of 2024 already today. Based on preliminary figures, Evonik achieved an adjusted EBITDA* of just under €522 million in the first quarter of 2024 (Q1 2023: €409 million), thus well above market expectations (analyst consensus disclosed by Vara Research on March 26, 2024: around €450 million). The Specialty Additives and Nutrition & Care divisions recorded the strongest growth. The upturn was driven by higher sales volumes: Following seven quarters of declines, volumes were above the previous year's level. In addition to a slight upturn in end customer demand, restocking in light of low inventory levels at customers also contributed to the higher volumes. According to preliminary figures, Evonik’s sales amounted to €3.796 billion in the first quarter of 2024, compared with €4.0 billion in the prior-year quarter. This was mainly due to declining sales prices as a result of lower raw material costs. Consensus expected this number to be approximately €3.883 billion. Evonik continues to expect adjusted EBITDA* of between €1.7 billion and €2.0 billion and sales of between €15 billion and €17 billion. Evonik Industries AG will publish final figures and the quarterly report for the first quarter 2024 as planned on May 8, 2024. *Notes on key performance indicators (KPIs) can be found in the Financial Report 2023 of Evonik Industries AG starting on page 240. The Financial Report 2023 is available at: Contact/person making the notification: End of Inside Information
16-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Evonik Industries AG |
| Rellinghauser Straße 1-11 | |
| 45128 Essen | |
| Germany | |
| Phone: | +49 (0) 201 177-01 |
| Fax: | +49 (0) 201 177-3475 |
| E-mail: | investor-relations@evonik.com |
| Internet: | www.evonik.com |
| ISIN: | DE000EVNK013 |
| WKN: | EVNK01 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
| EQS News ID: | 1881517 |
| End of Announcement | EQS News Service |
|
|
1881517 16-Apr-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 13.108,00 | 12.199,00 | 14.955,00 | 18.488,00 | 15.267,00 | 15.157,00 | 15.500,00 | |
| EBITDA1,2 | 2.153,00 | 1.837,00 | 2.246,00 | 2.510,00 | 1.598,00 | 1.694,00 | 1.800,00 | |
| EBITDA-Margin3 | 16,43 | 15,06 | 15,02 | 13,58 | 10,47 | 11,18 | 11,61 | |
| EBIT1,4 | 1.080,00 | 819,00 | 1.173,00 | 942,00 | -243,00 | 577,00 | 680,00 | |
| EBIT-Margin5 | 8,24 | 6,71 | 7,84 | 5,10 | -1,59 | 3,81 | 4,39 | |
| Net Profit (Loss)1 | 2.127,00 | 479,00 | 767,00 | 555,00 | -452,00 | 240,00 | 285,00 | |
| Net-Margin6 | 16,23 | 3,93 | 5,13 | 3,00 | -2,96 | 1,58 | 1,84 | |
| Cashflow1,7 | 1.321,00 | 1.727,00 | 1.815,00 | 1.650,00 | 1.594,00 | 1.713,00 | 0,00 | |
| Earnings per share8 | 4,52 | 1,00 | 1,60 | 1,16 | -1,00 | 0,48 | 0,64 | |
| Dividend per share8 | 1,15 | 1,15 | 1,17 | 1,17 | 1,17 | 1,17 | 1,17 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Evonik Industries | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| EVNK01 | DE000EVNK013 | AG | 8.919,24 Mio € | 25.04.2013 | Halten | 9F39C2X7+QJ |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 16,22 | 19,74 | 0,82 | 13,92 | 1,05 | 5,21 | 0,59 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 1,17 | 1,17 | 1,17 | 6,11% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 28.05.2025 | 12.05.2025 | 01.08.2025 | 04.11.2025 | 05.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -2,32% | +0,25% | +14,41% | +0,21% | -40,56% |
